Thomas Weisel Upgrades Genomic Health (GHDX) to Overweight
More News related to GHDX
- Genomic Health (GHDX) Tops Q3 EPS by 7c
- Genomic Health Announces Third Quarter 2009 Financial Results and Business Progress
- Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report
- Genomic Health to Announce Third Quarter 2009 Financial Results and Host Conference Call on Wednesday, November 4, 2009
- Genomic Health Announces Analyst Day Webcast Presentation to be Held on November 12, 2009
More News related to Upgrades
- Hertz Global (HTZ) Appoints Scott P. Sider as President of the Americas
- Noah Education Holdings (NED) Appoints Tang to President and COO and Jerry He to EVP and CFO
- Western Union (WU) Promotes Hikmet Ersek to COO
- Bruker Corp. (BRKR) Appoints Knight to COO and Monahan to CFO
- Rimage Corp (RIMG) To Promote Sherman Black to CEO and Board Member
Thomas Weisel upgrades Genomic Health (Nasdaq: GHDX) from Marketweight to Overweight. Price target $23.
To see more analyst ratings on GHDX Click Here.
Genomic Health, Inc., a life science company, engages in the development and commercialization of genomic-based clinical diagnostic tests for cancer.
Related Categories
UpgradesStocks Mentioned
-0.43Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
